Glamand Fashion News

DelveInsight’s, “Glioblastoma Pipeline Insight 2024” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including Glioblastoma clinical trials and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Glioblastoma Pipeline Report

• DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
• The leading Glioblastoma Companies working in the market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
• Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
• May 2024:- Ono Pharmaceuticals- A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy. The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
• April 2024:- Singlera Genomics Inc.- A Case-control, Non-intervention Study for Gastric Cancer Screening. The objective is to explore the clinical performance of polygene methylation (PCR-fluorescence probe) in the adjunctive diagnosis of gastric cancer, including the sensitivity of detection of various types and stages of gastric cancer, the specificity of detection of healthy controls, precancerous states, precancerous lesions, and the detection interference of other cancers. The diagnostic performance will be compared with CA199, CEA and CA724. The research data will provide a basis for screening targets for the development of detection kits.
• March 2024:- Vivian Wing Yan Lee- Cost-minimization Analysis of Xeloda® vs 5-fluorouracil-based Treatment for Gastric Cancer Patients in Hong Kong. This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong. Patient baseline characteristics and cost data will be extracted from records and compared.
• February 2024:- Ambrx, Inc.- A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression. This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.
• February 2024:- Bristol-Myers Squibb- A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma. The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

Request a sample and discover the recent advances in Glioblastoma Drugs @ Glioblastoma Pipeline Outlook Report

In the Glioblastoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. The assessment part of the report embraces, in-depth Glioblastoma commercial assessment and clinical assessment of the Glioblastoma pipeline products under development.

Glioblastoma Overview

The glioblastoma multiforme preferentially invades along myelinated axons, vascular basement membranes, and the subependyma, mostly occurring in the subcortical matter of the cerebrum (65%). Within the cerebrum, the tumors proliferate through the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes. However, tumor formation is rarely isolated exclusively to one of these lobes, instead presenting in a combination of these lobes within the cerebrum. GBM also forms in the hypothalamus-thalamus area (20%) and the cerebellum and posterior fossa (15%).

Find out more about Glioblastoma Analysis @ Glioblastoma Drugs

Glioblastoma Emerging Drugs Profile

• Enzastaurin: Denovo BioPharma
• Tofacitinib: Pfizer
• VT1021: Vigeo Therapeutics
• Varlilumab: Celldex Therapeutics
• Debio 0123: Debiopharm
• PRT3645: Prelude Therapeutics

Glioblastoma Therapeutics Assessment

There are approx. 195+ Glioblastoma companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma. The Glioblastoma pipeline report proffers an integral view of the emerging Glioblastoma segmented by stage, product type, molecule type, and route of administration.

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dive deep into rich insights for new Glioblastoma, visit @ Glioblastoma Treatment Landscape

Glioblastoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Glioblastoma Pipeline Report

• Coverage- Global
• Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
• Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

For further information on the Glioblastoma Pipeline Therapeutics, reach out @ Glioblastoma Therapeutics Segmentation

Table of Content

1. Introduction
2. Glioblastoma Executive Summary
3. Glioblastoma: Overview
4. Glioblastoma Pipeline Therapeutics
5. Glioblastoma Therapeutic Assessment
6. Glioblastoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Enzastaurin: Denovo BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Varlilumab: Celldex Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PRT3645: Prelude Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ELC-401: Elicera Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glioblastoma Key Companies
21. Glioblastoma Key Products
22. Glioblastoma- Unmet Needs
23. Glioblastoma- Market Drivers and Barriers
24. Glioblastoma- Future Perspectives and Conclusion
25. Glioblastoma Analyst Views
26. Glioblastoma Key Companies
27. Appendix

Find out more about Glioblastoma Therapeutics Assessment @ Glioblastoma Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/